Endocrine Abstracts

Introduction: Denosumab is an important treatment option for osteoporosis. Rebound hypercalcemia on discontinuation of denosumab is well documented. Denosumab can increase PTH, peaking within 2-4 weeks of administration and subsiding thereafter, therefore making diagnosis of primary hyperparathyroidism (pHPT) difficult. The aim of our case series is to review the calcium fluctuations in relationship to timing of denosumab administration and identify the possibility of rebound ...